Opendata, web and dolomites

DIALYBRID

Revolutionising the world of hemodialysis with a novel, hybrid, silk fibroin/polyurethane vascular access

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 DIALYBRID project word cloud

Explore the words cloud of the DIALYBRID project. It provides you a very rough idea of what is the project "DIALYBRID" about.

meet    market    36    de    frequency    integration    commercial    master    hypertension    saving    health    competitiveness    worldwide    sag    silk    2030    business    re    bottleneck    action    ftes    diversify    ip    limitations    members    blend    jobs    technological    reg    risk    arteriovenous    validation    human    38    patency    revolutionize    2025    society    certification    silkothane    infective    urgent    hemodialysis    msca    auspices    fibroin    placement    people    alternatives    costly    productivity    trl    trademarked    fact    sme    venture    patients    delivering    live    renal    soundness    reducing    remodeling    reached    therapy       frequent    portfolio    proposes    enter    granting    accesses    sustaining    opportunity    vascular    increment    life    viability    cannulation    consequence    verify    industrialization    turnover    view    create    skilled    nanostructured    manufactured    materials    clinical    quality    diabetes    54m    polyurethane    global    commercialization    28    electrospinning    470    innovative    hybrid    bel    functioning    scenario    longer    plan    million    interventions    semidegradable    complications    suffer    graft   

Project "DIALYBRID" data sheet

The following table provides information about the project.

Coordinator
BIOENGINEERING LABORATORIES 

Organization address
address: VIA VIVALDI 32/A
city: CANTU'
postcode: 22063
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Project website http://www.bioengineeringlab.com/eng/sme-instrument-phase-1-dialybrid-december-1-2018/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOENGINEERING LABORATORIES IT (CANTU') coordinator 50˙000.00

Map

 Project objective

Vascular access is the bottleneck to long-term hemodialysis for about 2.2 million people worldwide who need this life-saving/life-sustaining therapy in case of renal failure, e.g. as a consequence of diabetes and/or hypertension. The current alternatives of vascular access suffer in fact from several limitations, e.g. the need for frequent and costly re-interventions, reduced patency, infective complications. To meet this urgent, global, clinical need, BEL proposes SAG (Silkothane® Arteriovenous Graft), an innovative, hybrid, semidegradable, nanostructured vascular access, manufactured by electrospinning using Silkothane®, a silk fibroin/polyurethane blend developed and trademarked by BEL under the auspices of a MSCA action. Enabling early cannulation and easy placement, as well as remodeling, patency, and integration on the long term, SAG will revolutionize the scenario of hemodialysis vascular accesses worldwide by: reducing the frequency of complications and re-interventions (thus health costs); granting broader access to hemodialysis; improving the patients’ quality of life, enabling them to live longer as functioning members of the society. SAG has reached TRL 6. Phase 1 would allow BEL to verify the soundness of SAG’s venture (with a Business Plan and an IP Management Plan), and to de-risk the technological viability of the industrialization (delivering Essential Requirements, Risk Analysis, Validation Master Plan, Industrialization Plan), in view of future clinical studies, certification and commercialization. SAG represents for BEL an important opportunity to diversify its product portfolio, enter the market of Advanced Materials, experience growth in productivity and competitiveness and create new jobs. As the commercial potential of SAG is estimated to be around 28 million € in 2025 and 54M€ in 2030, in 2025 the SME would experience an increment in turnover of about 470%, and a 36% increase (from 28 FTEs to 38 FTEs) in highly skilled human resources.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIALYBRID" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DIALYBRID" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

VINOQUANT11SUPERPLUS (2019)

A digital based system for measuring, showing and regulation of the complexe system of wine feremtation with high precision via a Bluetooth -Refractometer, a Software and a Bluetooth Thermostat

Read More  

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More